Tagged with generic

Philippines Ravinder S. Singha, the Managing Director of Firmlink Pharma, discusses the unique business model they offer to their clients, their key success factors in entering new and sometimes challenging markets, as well as his views on the potential seen in many of the dynamic pharma markets around the world. He…

Philippines Jingle Garcia Diola, Executive Director at Firmlink Pharma, details the company’s value-added services and how they are positioning themselves as the business development partner of choice for large local and multinational companies looking to penetrate new markets. She also discusses her extensive career in the pharmaceutical industry as well as…

Greece As the President of the Panhellenic Union of Pharmaceutical Industries (PEF), Theodore Tryfon shares the mission of the association, the main challenges plaguing the sector, as well as the measures in place to mitigate the difficult economic times and elevate the Greek brand in the upcoming years. As an introduction…

Switzerland Beat Berger (BB) and Dr Uwe Schmelzer (US) of Swiss API distributor DCS Pharma discuss growth segments in the global generics market, international hotspots, and the benefits of being based in Switzerland.   As an API distributor, what segments of the global generics market do you see the most growth…

Taiwan Kao Su-Chin Chang, founder and chairman of Weidar Chemical and Pharmaceutical, describes the robust development and international expansion of this historical domestic pharmaceutical manufacturer and the company’s enduring commitment to maintaining the excellence of its manufacturing capacity, which has allowed Weidar to establish itself as one of the foremost generics…

Philippines Bert van Dierendonck and Alec van Dierendonck, Founder and Country Manager, as well as father and son, discuss Euro Generics’ unique history in the country and their road to becoming one of the fastest growing pharmaceutical companies in the Philippines. They also discuss their strategies for staying ahead of market…

Philippines Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the booming generic industry over the past years has helped to expand access to affordable medications to the Filipinos, still pointing out that there is much room for expansion in…

Singapore Teva’s recently appointed SVP of APAC and MENA Vivek Bachhawat details his relatively seamless journey from Actavis to Teva and the synergies inherent in both organizations even prior to the merger. He also highlights the company’s continued commitment to Singapore and its key regional role which will grow in importance…

Mexico José Angel García Hinojosa, counsellor of the board of the Grupo Loeffler Russek, details how Loeffler’s impressive growth has forced the company to increase their manufacturing capacity. While Loeffler grew from a small Mexican business to one of the most prominent generics companies in the fast-growing Mexican market, Mr. García…

Mexico The General Directors of Rayere explain how the historical Mexican pharma company has been leveraging its outstanding manufacturing capacity and product development expertise to become a thriving and reputed player in the patented segment, while the company now envisions to bring its high-quality quality products to international markets. Rayere boasts…

Philippines In an exclusive interview, Kamal Abichandani, Deepu Bhatia, Hersh Abichandani, Richard Mayani, the Chairman, Director, General Manager, and Information Systems Manager of Ambica tell their story and reveal their key to success: quality partnerships. As a former engineer without previous experience in the pharmaceutical industry, what were some of the ambitions that…

Slovakia Genas’ Michaela Palagyi shares the association’s pride in being an affiliate member of Medicines for Europe and how this allows them to liaise more closely with their European counterparts. She also reveals the share of generics in today’s Slovak pharma market: around 60 per cent of volume and slightly less…